Bristol-Myers Squibb Company (BMY) · page 62 of 197
The slide uses a line chart to contrast the revenue decay curves of small molecules vs biologics to argue that Celgene's portfolio is structurally vulnerable.
Activist deck · expose_contradiction · expose_contradiction · dense density
Slide locked Sign in to view
Slide schematic 6/7
callout 1/1 chart 1/1 list 1/1 metric 0/1 paragraph 1/1 source-note 1/1 title 1/1
1 without position metric 1
metric · primary
Components 7
primary line bullet primary paragraph source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1